ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion.
The sale means Ono Pharmaceutical takes ownership of Qinlock, an already approved cancer therapeutic, and another drug candidate that will be coming under consideration for approval by the US FDA in the next few months.
The definitive merger agreement constitutes ONO buying all available shares of Deciphera, for US$25.60 per share in cash, bringing the total value of the merger to US$2.4 billion, one of the largest purchases in the pharma industry for the year. Deciphera will continue as a fully owned subsidiary of ONO Pharmaceutical.
“We expect that this acquisition of Deciphera will not only expand ONO's target oncology portfolio, but also accelerate ONO's business development in the United States and Europe, and strengthen kinase drug discovery research,” ONO’s CEO Gyo Sagara explained.
Deciphera focuses on innovative cancer therapeutics, and specialises in kinase biology. Currently, they have one drug as a mainstay in the market. The therapy, QINLOCK® (ripretinib), is a KIT inhibitor, and approved in over 40 countries for the treatment of fourth-line gastrointestinal stromal tumour.
The other therapeutic in the Deciphera pipeline is Vimseltinib, a CSF-1R inhibitor, which has demonstrated statistically significant and clinically meaningful efficacy when tested in patients with tenosynovial giant cell tumours, in the Phase III MOTION trial. The results will be used to evaluate the drug for approval by US and EU bodies by the end of the year.
The addition of these therapeutics will strengthen ONO Pharmaceutical’s oncology pipeline, which they are trying to expand. The merger follows on from a drug discovery collaboration agreement with PRISM BioLab. The new partnership hopes to accelerate drug discovery in the oncology space by to identifying and developing drug candidates of a protein-protein interaction (PPI) target, using PRISM’s proprietary PepMetics® technology.
“We are actively engaged in creating innovative drugs through open innovation to address unmet medical needs across a wide range of diseases,” stated Seishi Katsumata, Executive Director, Discovery & Research of ONO.
Sagara stated:
“We expect that this acquisition of Deciphera will not only expand ONO’s targeted oncology portfolio, but also accelerate ONO’s business development in the United States and Europe, and strengthen kinase drug discovery research. Deciphera’s mission statement “Inspired by Patients: Defeat Cancer” is aligned with ONO’s corporate philosophy “Dedicated to the Fight against Disease and Pain.” We respect the innovative culture of Deciphera and look forward to working together to drive further growth for both ONO and Deciphera.”
Sources:
1. ONO Pharma. ONO Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals. [Date accessed 01/05/2024] www.ono-pharma.com/en/news/20240430.html
2. ONO Pharma. ONO Enters into a Collaboration Agreement with PRISM BioLab to Generate Novel Drug Candidates in the Oncology Area. [Date accessed 01/05/2024] www.ono-pharma.com/en/news/20240425.html
Related News
-
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc... -
News Key takeaways from Saudi Arabia's National Biotechnology Strategy
In January 2024, Saudi Arabia released its National Biotech Strategy, an ambitious plan to localise biomanufacturing, incentivise R&D and establish the Kingdom as the regional biotech leader by 2030, and an internationally recognised hub by 2040. -
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance